Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External AffairsBusiness Wire • 10/05/21
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and DermatomyositisBusiness Wire • 08/23/21
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business UpdatesBusiness Wire • 08/12/21
Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021Business Wire • 07/08/21
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021Business Wire • 06/02/21
Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of DirectorsBusiness Wire • 06/01/21
Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/27/21
Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021Business Wire • 05/26/21
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business UpdatesBusiness Wire • 05/12/21
Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual MeetingBusiness Wire • 04/10/21
Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business UpdatesBusiness Wire • 03/11/21
Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care ConferenceBusiness Wire • 02/25/21
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect ConferenceBusiness Wire • 01/07/21
Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business UpdatesBusiness Wire • 11/05/20
Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020Business Wire • 11/05/20
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and DermatomyositisBusiness Wire • 10/23/20
Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific ConferencesBusiness Wire • 10/15/20
Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of RheumatologyBusiness Wire • 09/17/20